Alpharmaxim full lockup logo

Embracing European Reference Networks for patient engagement

Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020

Embracing European Reference Networks (ERNs) for patient engagement

Awareness of ERNs and education around their potential involvement needs to be a core focus to ensure that patients are at the centre of drug and trial development. Alpharmaxim have a deep understanding of the field of rare diseases and the challenges faced by patients in this unique area.

  • Patients are at the heart of the focus of ERNs
  • It can be challenging for patient groups and organisations to access ERNs
  • Involving ERNs and patients at the earliest stage in the drug development process will help to ensure that patient-reported outcomes are realistic and achievable, ensuring that patient outcomes are improved

Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.

“This is a good time for us to try and ride the wave of greater solidarity and think about our fellow people and trying to support everybody, even if they have no condition.”

Victoria Hedley, Rare Disease Policy Manager, Newcastle University

Talk to us about how we can transform your communications

World Parkinson's Day 2023

World Parkinson's Day 2023

For World Parkinson’s Day 2023, Alpharmaxim created an animation to highlight some of the Parkinson's symptoms to look out for – in yourself and others.
We need to talk about vaccine hesitancy

We need to talk about vaccine hesitancy

Why do some individuals opt out of vaccination or prevent their children from being vaccinated? Are all forms of hesitancy or rejection illogical?
Let's talk about vaccine hesitancy

Let's talk about vaccine hesitancy

Vaccination can be a complex, personal matter, and there are a number of reasons why individuals may be hesitant.